Program
monalizumab
Also written as “Monalizumab”, “NNC 0141-0000-0100” and “Durvalumab + Monalizumab”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of Head and Neck · Head and Neck Neoplasms · Colonic Neoplasms · Leukemia, Lymphocytic, Chronic, B-Cell, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 53 open or running | phase 3since Sep 23, 2020 | Dec 10, 2018 | Jan 8, 2027phase 3 · NCT05221840 |
| Innate Pharma | 40 open or running | phase 2since Jan 2, 2015 | May 31, 2011 | none ahead |
- Named in AstraZeneca’s own pipeline as
monalizumab
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 31, 2011First study: phase 1 study in InflammationNew to Innate PharmaInnate Pharma · NCT01370902 · 92 enrolled · Germany
- Jan 2, 2015Phase 2 study in Squamous Cell Carcinoma of Head and NeckInnate Pharma · NCT02331875 · 3 enrolled · Germany, Spain
- Sep 22, 2015Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellInnate Pharma · NCT02557516 · 22 enrolled · United States
- Dec 17, 2015Phase 2 study in Head and Neck NeoplasmsInnate Pharma · NCT02643550 · 143 enrolled · United States, France
- Dec 10, 2018AstraZeneca's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to AstraZenecaAstraZeneca · NCT03822351 · 189 enrolled · United States, Canada, France and more
- Oct 16, 2019Phase 2 study in Colonic NeoplasmsAstraZeneca · NCT04145193
- Sep 23, 2020Phase 3 study in Squamous Cell Carcinoma of Head and NeckAstraZeneca · NCT04590963 · 370 enrolled · United States, Argentina, Australia and more
- Sep 20, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05061550 · 630 planned · United States, Belgium, Canada and more
- Jan 14, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05221840 · 1,051 enrolled · United States, Australia, Brazil and more
- Nov 4, 2026Primary completion moved from 2026-09-30 to 2027-01-08Date moved laterphase 3 · +3 months · NCT05221840
Ahead
- Jan 8, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05221840
- May 28, 2030Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05061550
TargetBeta
“A humanized immunoglobulin G4 (IgG4) monoclonal antibody against the human natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), with potential antineoplastic activity. Upon administration, monalizumab binds to NKG2A and prev…”NCIt, read by Claude
Other programs on KLRC1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-NKG2A/Anti-PD-L1 Bispecific Antibody XB628rule | Exelixis | phase 1 | 1 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05221840Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more | 3 | Active, not recruiting | AstraZeneca | Jan 8, 2027 | 1,051 |
| NCT05061550Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 2 | Recruiting | AstraZeneca | May 28, 2030 | 630 |
| NCT04590963Squamous Cell Carcinoma of Head and Neck · United States, Argentina, Australia and more | 3 | Active, not recruiting | AstraZeneca | May 11, 2022 | 370 |
| NCT04145193Colonic Neoplasms | 2 | Withdrawn | AstraZeneca | Mar 19, 2024 | 0 |
| NCT03822351Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more | 2 | Completed | AstraZeneca | Jul 18, 2023 | 189 |
| NCT02643550Head and Neck Neoplasms · United States, France | 2 | Completed | Innate Pharma | Mar 28, 2023 | 143 |
| NCT02557516Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Terminated | Innate Pharma | Oct 29, 2018 | 22 |
| NCT02331875Squamous Cell Carcinoma of Head and Neck · Germany, Spain | 2 | Terminated | Innate Pharma | Dec 2016 | 3 |
| NCT01370902Inflammation · Germany | 1 | Completed | Innate Pharma | Mar 2014 | 92 |
How it is read
Names in the registry
- “Monalizumab”, 4 entries
- “NNC 0141-0000-0100”, 3 entries
- “Durvalumab + Monalizumab”, 1 entry
- “E3 - mFOLFOX6, durvalumab and monalizumab”, 1 entry
- “monalizumab”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Squamous Cell Carcinoma of Head and Neck, 2 studies
- Head and Neck Neoplasms, 1 study
- Colonic Neoplasms, 1 study
- Leukemia, Lymphocytic, Chronic, B-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.